Shanshan Lai

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) poses an increasing threat to global public health. Currently approved drugs for MASLD, such as resmetirom and semaglutide, have demonstrated clinical efficacy. However, their use is associated with notable adverse...